Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects

NCT04453852 is registered in ClinicalTrials.gov with Vaxine Pty Ltd as lead sponsor.

NCT NCT04453852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04453852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects
Lead sponsor
Vaxine Pty Ltd
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2020
Completion date
April 14, 2021
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infection, covid